Gilead Collaborates with Goldfinch Bio to Develop and Commercialize Therapies for Kidney Disorders

Shots:

• Goldfinch to receive $55M upfront including $5M equity investment, $1.95B milestones for the first five opted programs and royalties on sales of products, retaining the option for lead development & co-promotion of optioned products targeting kidney disease plus equal development cost/profit share in the US 
• Gilead to get an exclusive option to license WW rights for the therapies, developed by Goldfinch’s Kidney Genome Atlas (KGA) and is responsible for development & commercialization of optioned products. Gilead to provide the $54M fund to Goldfinch KGA’s program for DKD
• Goldfinch’s Kidney Genome Atlas program enables the discovery of genetic variants associated with kidney disease and will expand it in orphan kidney diseases including DKD

Click here to read full press release/ article | Ref: Gilead | Image: Third Rock Ventures